TPCW
OCUL icon

TD Private Client Wealth’s Ocular Therapeutix OCUL Stock Holding History

TD Private Client Wealth’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795 Hold
81
– – ﹤0.01% 1503
2026
Q1 		$686 Buy
+81
New +$772 ﹤0.01% 1452

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Private Client Wealth's OCUL Position: Q2 2026 in Review

TD Private Client Wealth held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 81 shares worth $795. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

TD Private Client Wealth first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • TD Private Client Wealth held 81 shares of Ocular Therapeutix worth $795 as of Q2 2026.
  • TD Private Client Wealth left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1503 holding.
  • TD Private Client Wealth first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.